Natural antigenic peptides of gastric signet ring cell carcinomas

N. Sato, Y. Okada, K. Suzuki, H. Sahara, T. Yasoshima, Y. Hirohashi, Y. Nabeta, I. Hirai, T. Torigoe, S. Takahashi, N. Takahashi, A. Sasaki, M. Suzuki, J. Hamuro, H. Ikeda, Y. Wada, K. Hirata, K. Kikuchi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Recent human tumor immunology research has identified several genes coding immunogenic peptides recognized by cytotoxic T lymphocytes (CTL) in melanoma tumors. However, such peptides in tumors of epithelial cell origins with clinically high incidence, such as stomach, colon, lung, etc., have not yet been determined. In this paper we describe a human leukocyte antigen (HLA)-A31 (A*31012)-restricted natural antigenic peptide recognized by the CTL clone, TcHST-2, of gastric signet ring cell carcinoma HST-2. This peptide was designated F4.2, and was composed of ten amino acid residues with two anchor motif residues necessary for binding to HLA-A31 molecules. The synthetic F4.2 peptide could enhance the reactivity of TcHST-2 against HST-2 cells. Furthermore, introduction of a minigene coding F4.2 peptide to HLA-A31 (+) HOBC8-A31-12 cells conferred cytotoxic susceptibility on the cells to TcHST-2. Some of the HLA-A31 gene-introduced stomach cancer lines, such as MKN28-A31-2, were lysed by TcHST-2, suggesting the presence of F4.2 peptide in at least some HLA-A31 (+) stomach cancers. Using immunoprecipitates made with cell lysates of MKN28-A31-2 and anti-HLA-A31 specific monoclonal antibody (mAb) 2D12 as well as mass spectrometry, it was indicated that this peptide may be expressed in MKN28-A31-2 cells. Our studies suggested that F4.2 peptide may act as the immunogenic peptide in HLA-A31 (+) stomach cancer patients.

Original languageEnglish
Pages (from-to)31-41
Number of pages11
JournalGann Monographs on Cancer Research
Volume48
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Signet Ring Cell Carcinoma
HLA Antigens
Stomach
Peptides
Stomach Neoplasms
Cytotoxic T-Lymphocytes
Neoplasms
Allergy and Immunology
Genes
Melanoma
Mass Spectrometry
Colon
Clone Cells
Epithelial Cells
Monoclonal Antibodies
Amino Acids
Lung
peptide F4.2
Incidence

ASJC Scopus subject areas

  • Cancer Research

Cite this

Sato, N., Okada, Y., Suzuki, K., Sahara, H., Yasoshima, T., Hirohashi, Y., ... Kikuchi, K. (1999). Natural antigenic peptides of gastric signet ring cell carcinomas. Gann Monographs on Cancer Research, 48, 31-41.

Natural antigenic peptides of gastric signet ring cell carcinomas. / Sato, N.; Okada, Y.; Suzuki, K.; Sahara, H.; Yasoshima, T.; Hirohashi, Y.; Nabeta, Y.; Hirai, I.; Torigoe, T.; Takahashi, S.; Takahashi, N.; Sasaki, A.; Suzuki, M.; Hamuro, J.; Ikeda, H.; Wada, Y.; Hirata, K.; Kikuchi, K.

In: Gann Monographs on Cancer Research, Vol. 48, 1999, p. 31-41.

Research output: Contribution to journalArticle

Sato, N, Okada, Y, Suzuki, K, Sahara, H, Yasoshima, T, Hirohashi, Y, Nabeta, Y, Hirai, I, Torigoe, T, Takahashi, S, Takahashi, N, Sasaki, A, Suzuki, M, Hamuro, J, Ikeda, H, Wada, Y, Hirata, K & Kikuchi, K 1999, 'Natural antigenic peptides of gastric signet ring cell carcinomas', Gann Monographs on Cancer Research, vol. 48, pp. 31-41.
Sato N, Okada Y, Suzuki K, Sahara H, Yasoshima T, Hirohashi Y et al. Natural antigenic peptides of gastric signet ring cell carcinomas. Gann Monographs on Cancer Research. 1999;48:31-41.
Sato, N. ; Okada, Y. ; Suzuki, K. ; Sahara, H. ; Yasoshima, T. ; Hirohashi, Y. ; Nabeta, Y. ; Hirai, I. ; Torigoe, T. ; Takahashi, S. ; Takahashi, N. ; Sasaki, A. ; Suzuki, M. ; Hamuro, J. ; Ikeda, H. ; Wada, Y. ; Hirata, K. ; Kikuchi, K. / Natural antigenic peptides of gastric signet ring cell carcinomas. In: Gann Monographs on Cancer Research. 1999 ; Vol. 48. pp. 31-41.
@article{7bfa49686d65410eb77c6f2e8c545e09,
title = "Natural antigenic peptides of gastric signet ring cell carcinomas",
abstract = "Recent human tumor immunology research has identified several genes coding immunogenic peptides recognized by cytotoxic T lymphocytes (CTL) in melanoma tumors. However, such peptides in tumors of epithelial cell origins with clinically high incidence, such as stomach, colon, lung, etc., have not yet been determined. In this paper we describe a human leukocyte antigen (HLA)-A31 (A*31012)-restricted natural antigenic peptide recognized by the CTL clone, TcHST-2, of gastric signet ring cell carcinoma HST-2. This peptide was designated F4.2, and was composed of ten amino acid residues with two anchor motif residues necessary for binding to HLA-A31 molecules. The synthetic F4.2 peptide could enhance the reactivity of TcHST-2 against HST-2 cells. Furthermore, introduction of a minigene coding F4.2 peptide to HLA-A31 (+) HOBC8-A31-12 cells conferred cytotoxic susceptibility on the cells to TcHST-2. Some of the HLA-A31 gene-introduced stomach cancer lines, such as MKN28-A31-2, were lysed by TcHST-2, suggesting the presence of F4.2 peptide in at least some HLA-A31 (+) stomach cancers. Using immunoprecipitates made with cell lysates of MKN28-A31-2 and anti-HLA-A31 specific monoclonal antibody (mAb) 2D12 as well as mass spectrometry, it was indicated that this peptide may be expressed in MKN28-A31-2 cells. Our studies suggested that F4.2 peptide may act as the immunogenic peptide in HLA-A31 (+) stomach cancer patients.",
author = "N. Sato and Y. Okada and K. Suzuki and H. Sahara and T. Yasoshima and Y. Hirohashi and Y. Nabeta and I. Hirai and T. Torigoe and S. Takahashi and N. Takahashi and A. Sasaki and M. Suzuki and J. Hamuro and H. Ikeda and Y. Wada and K. Hirata and K. Kikuchi",
year = "1999",
language = "English",
volume = "48",
pages = "31--41",
journal = "Gann Monographs on Cancer Research",
issn = "0072-0151",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Natural antigenic peptides of gastric signet ring cell carcinomas

AU - Sato, N.

AU - Okada, Y.

AU - Suzuki, K.

AU - Sahara, H.

AU - Yasoshima, T.

AU - Hirohashi, Y.

AU - Nabeta, Y.

AU - Hirai, I.

AU - Torigoe, T.

AU - Takahashi, S.

AU - Takahashi, N.

AU - Sasaki, A.

AU - Suzuki, M.

AU - Hamuro, J.

AU - Ikeda, H.

AU - Wada, Y.

AU - Hirata, K.

AU - Kikuchi, K.

PY - 1999

Y1 - 1999

N2 - Recent human tumor immunology research has identified several genes coding immunogenic peptides recognized by cytotoxic T lymphocytes (CTL) in melanoma tumors. However, such peptides in tumors of epithelial cell origins with clinically high incidence, such as stomach, colon, lung, etc., have not yet been determined. In this paper we describe a human leukocyte antigen (HLA)-A31 (A*31012)-restricted natural antigenic peptide recognized by the CTL clone, TcHST-2, of gastric signet ring cell carcinoma HST-2. This peptide was designated F4.2, and was composed of ten amino acid residues with two anchor motif residues necessary for binding to HLA-A31 molecules. The synthetic F4.2 peptide could enhance the reactivity of TcHST-2 against HST-2 cells. Furthermore, introduction of a minigene coding F4.2 peptide to HLA-A31 (+) HOBC8-A31-12 cells conferred cytotoxic susceptibility on the cells to TcHST-2. Some of the HLA-A31 gene-introduced stomach cancer lines, such as MKN28-A31-2, were lysed by TcHST-2, suggesting the presence of F4.2 peptide in at least some HLA-A31 (+) stomach cancers. Using immunoprecipitates made with cell lysates of MKN28-A31-2 and anti-HLA-A31 specific monoclonal antibody (mAb) 2D12 as well as mass spectrometry, it was indicated that this peptide may be expressed in MKN28-A31-2 cells. Our studies suggested that F4.2 peptide may act as the immunogenic peptide in HLA-A31 (+) stomach cancer patients.

AB - Recent human tumor immunology research has identified several genes coding immunogenic peptides recognized by cytotoxic T lymphocytes (CTL) in melanoma tumors. However, such peptides in tumors of epithelial cell origins with clinically high incidence, such as stomach, colon, lung, etc., have not yet been determined. In this paper we describe a human leukocyte antigen (HLA)-A31 (A*31012)-restricted natural antigenic peptide recognized by the CTL clone, TcHST-2, of gastric signet ring cell carcinoma HST-2. This peptide was designated F4.2, and was composed of ten amino acid residues with two anchor motif residues necessary for binding to HLA-A31 molecules. The synthetic F4.2 peptide could enhance the reactivity of TcHST-2 against HST-2 cells. Furthermore, introduction of a minigene coding F4.2 peptide to HLA-A31 (+) HOBC8-A31-12 cells conferred cytotoxic susceptibility on the cells to TcHST-2. Some of the HLA-A31 gene-introduced stomach cancer lines, such as MKN28-A31-2, were lysed by TcHST-2, suggesting the presence of F4.2 peptide in at least some HLA-A31 (+) stomach cancers. Using immunoprecipitates made with cell lysates of MKN28-A31-2 and anti-HLA-A31 specific monoclonal antibody (mAb) 2D12 as well as mass spectrometry, it was indicated that this peptide may be expressed in MKN28-A31-2 cells. Our studies suggested that F4.2 peptide may act as the immunogenic peptide in HLA-A31 (+) stomach cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0033302996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033302996&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033302996

VL - 48

SP - 31

EP - 41

JO - Gann Monographs on Cancer Research

JF - Gann Monographs on Cancer Research

SN - 0072-0151

ER -